Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells

Immunopharmacology

Volumn 40, Issue 1, 1998, Pages 11-20

  Rowland, Tom L ^a   McHugh, Simon M ^a   Deighton, John ^a   Dearman, Rebecca J ^b   Ewan, Pamela W ^a   Kimber, Ian ^b  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Cytokines; Dexamethasone; Immunomodulation; Thalidomide

Indexed keywords

CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; PHYTOHEMAGGLUTININ; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD CELL; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOMODULATION; MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; DEXAMETHASONE; DIMETHYL SULFOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHORESIS, AGAR GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-4; INTERLEUKIN-6; PHYTOHEMAGGLUTININS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0031669267     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(98)00010-1     Document Type: Article

References (32)

1. Auphan N., DiDonato J.A., Rosette C., Helmburg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-Kb activity through induction of IkB synthesis. Science. 270:1995;286.
2. Baraniuk J.N. Steroids in asthma: molecular mechanisms of glucocorticoid actions. J. Allergy Clin. Immunol. 97:1996;141-177.
3. Battegay E.J. Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J. Mol. Med. 73:1995;333-346.
4. Beauparlant P., Hiscott J. Biological and biochemical inhibitors of the NF-κB/Rel proteins and cytokine synthesis. Cytokine Growth Factor Rev. 7:1996;175-190.
5. Bouaboula M., Legoux P., Pessegue B., Delpech B., Dumont X., Piechaczyk M., Casellas P., Shire D. Standardization of mRNA titration using a polymerase chain reaction method involving co-amplification with a multispecific internal control. J. Biol. Chem. 267:1992;21830-21838.
6. Carlesimo M., Giustini S., Rossi A., Bonaccorsi P., Calvieri S. Treatment of cutaneous and pulmonary sarcoidosis with thalidomide. J. Am. Acad. Dermatol. 32:1995;866-869.
7. D'Amato R.J., Loughnan M.S., Flynn E., Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc. Natl. Acad. Sci. USA. 91:1994;4082-4085.
8. Fernandez L.P., Schlegel P.G., Baker J., Chen Y., Chao N.J. Does thalidomide affect IL-2 response and production? Exp. Hematol. 23:1995;978-985.
9. Keenan R.J., Eiras G., Burckart G.J., Stuart R.S., Hardesty R.L., Vogelsang G., Griffith B.P., Zeevi A. Immuno suppressive properties of thalidomide. Inhibition of in-vitro lymphocyte proliferation alone and in combination with cyclosporin or FK506. Transplantation. 52:1991;908-910.
10. Larsson H. Treatment of severe colitis in Behcet's syndrome with thalidomide (CG-217). J. Int. Med. 228:1990;405-407.
11. Lenz W. Thalidomide and congenital abnormalities. Lancet. 1:1962;45-48.
12. Makonkawkeyoon S., Limson-Pobre R.N., Moreira A.L., Schauf V., Kaplan G. Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA. 90:1993;5974-5978.
13. McBride W.G. Thalidomide and congenital abnormalities. Lancet. 2:1961;1958-1960.
14. McHugh S., Rowland T. Thalidomide and derivatives: immunological investigations of TNF-α inhibition suggests drugs capable of selective gene regulation. Clin. Exp. Immunol. 110:1997;151-154.
15. McHugh S.M., Wilson A.B., Deighton J., Lachmann P.J., Ewan P.W. The profiles of interleukin (IL)-2, IL-6 and interferon-γ production by peripheral blood mononuclear cells from house dust mite allergic patients: a role for IL-6 in allergic disease. Allergy. 49:1994;751-759.
16. McHugh S.M., Rifkin I.R., Deighton J., Wilson A.B., Lachmann P.J., Lockwood C.M., Ewan P.W. The immunosuppressive drug thalidomide induces T helper cell type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures. Clin. Exp. Immunol. 99:1995;160-167.
17. Neubert R., Nogueira A.C., Neubert D. Thalidomide and the immune system: 2. Changes in receptors on blood cells of a healthy volunteer. Life Sci. 51:1992;2107-2116.
18. Nogueira A.C., Neubert R., Helge H., Neubert D. Thalidomide and the immune system: 3. Simultaneous up- and down-regulation of different integrin receptors on human white blood cells. Life Sci. 55:1994;77-92.
19. Postema P.T., den-Haan P., van-Hagen P.M., van-Blankenstein M. Treatment of colitis in Behcet's disease with thalidomide. Eur. J. Gastroenterol. Hepatol. 8:1996;929-931.
20. Powell R.J. New roles for thalidomide [editorial]. B.M.J. 313:1996;377-378.
21. Ramierz F., Fowell D.J., Puklavec M., Simmonds S., Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. J. Immunol. 156:1996;2406-2412.
22. Rasband W.S., Bright D.S. NIH image: a public domain image processing program for the macintosh. Microbeam Anal. Soc. J. 4:1995;137-149.
23. Sampaio E.P., Sarno E.N., Galilly R., Cohn Z.A., Kaplan G. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J. Exp. Med. 173:1991;699-703.
24. Sampaio E.P., Kaplan G., Miranda A., Nery J.A., Miguel C.P., Viana S.M., Sarno E.N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J. Infect. Dis. 168:1993;408-414.
25. Santos-Mendoza T., Favila-Castillo L., Oltra A., Tamariz J., Labarrios F., Estrada-Parra S., Estrada-Garcia L. Thalidomide and its metabolites have no effect on human lymphocyte proliferation. Int. Arch. Allergy Immunol. 111:1996;13-17.
26. Scheinman R.I., Cogswell P.C., Lofquist A.K., Baldwin A. Jr. Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science. 270:1995;283-286.
27. Schumacher H., Smith R.L., Williams R.T. The metabolism of thalidomide: the spontaneous hydrolysis of thalidomide in solution. Br. J. Pharmacol. 25:1965;324-337.
28. Shannon E.J., Sandoval F. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with Concanavalin-A, Staphylococcal enterotoxin A, and purified protein derivative. Immunopharmacology. 31:1995;109-116.
29. Thomas L., Ducros B., Secchi T., Balme B., Moulin G. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review. Arch. Dermatol. 129:1993;1261-1264.
30. Tsai E.Y., Jain J., Pesavento P.A., Rao A., Goldfeld A.E. Tumor necrosis factor α gene regulation in activated T cells involves ATF-2/Jun and NFATp. Mol. Cell Biol. 16:1996;459-467.
31. Turk B.E., Jiang H., Liu J.O. Binding of thalidomide to α 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor α production. Proc. Natl. Acad. Sci. USA. 93:1996;7552-7556.
32. Vogelsang G.B., Farmer E.R., Hess A.D., Altamonte V., Beschorner W.E., Jabs D.A., Corio R.L., Levin L.S., Covin O.M., Wingard J.R., Santos G.W. Thalidomide for the treatment of chronic graft-versus-host disease. New Engl. J. Med. 326:1992;1055-1058.